ABSTRACT
PURPOSE To evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO).
METHODS In this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections (IVI) in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of visual acuity outcomes were reported for all eyes over a 4-year observation period.
RESULTS Our cohort includes 2616 DMO eyes of 1965 patients over 48 months. Cox proportional hazards modelling identified injection number (hazard ratio [HR] = 1.18), male gender (HR = 1.13), and baseline VA (HR = 1.09) as independent predictors to reach a favorable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 by 14.7 months.
CONCLUSION To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our dataset available on an open-source data repository as a resource for all clinical researchers globally.
SYNOPSIS Using time-to-event analysis in patients receiving anti-VEGF for DMO: age, baseline visual acuity and injection number are independent predictors of visual outcomes.
Competing Interest Statement
Mixed competing interests: “All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Dr. Balaskas reports grants from Bayer AG, personal fees from Alimera, from Allergan, outside the submitted work; Dr. Keane reports other from Big Picture Eye Health, during the conduct of the study; personal fees from DeepMind, personal fees from Optos, personal fees from Novartis, personal fees from Bayer, personal fees from Allergan, personal fees from Heidelberg Engineering, personal fees from Topcon, personal fees from Carl Zeiss Meditec, personal fees from Haag Streit, personal fees from Santen, grants from National Institute for Health Research, grants from Fight For Sight UK, outside the submitted work; Dr. Kortuem reports personal fees from Big Picture Eye Health, during the conduct of the study; grants and personal fees from Novartis Pharma, grants and personal fees from Bayer Pharma, personal fees from Zeiss, personal fees from Allergan, personal fees from Alcon, personal fees from Google Deepmind, Dr. Sim reports other from Big Picture Eye Health, during the conduct of the study; personal fees from Allergan, personal fees from Novartis, personal fees from Bayer, personal fees from Big Picture Eye Health, personal fees from Haag Streit, outside the submitted work; Dr. Patel reports grants and other from Bayer, other from Novartis, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.” Dr. Hamilton, Dr. Kern, Dr. Fu Dr. Huemer, Dr. Wagner and Dr. Faes have nothing to disclose.
Funding Statement
No funding has been received for this work
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
An anonymised version of the dataset as well as the code used for analysis is available in the open source digital repository Dryad.
